Dotarem

Phase 2Small molecule

Bayer

Dotarem is one of 67 small molecule programs targeting Interstitial Lung Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial Lung DiseaseRecruiting

Alzheimer's DiseaseNot yet recruiting

Interstitial Lung DiseasePhase 2

Recruiting

Alzheimer's DiseasePhase 1

Not yet recruiting

Competition

Competitive Landscape

54 competitors in Alzheimer's Disease

#DrugCompanyPhaseTrials

Aricept

Eisai

Approved

31 2

Leqembi

Eisai

Phase 3

6 3

Nuplazid

AACADIA Pharmaceuticals Inc.

Ozempic

3 5

Namenda

AbbVie

Phase 2

2 6

Briviact

UCB

Phase 2

1 7

Leukine

Sanofi

Phase 2

1 8

Niacor

AbbVie

Phase 2

1 9

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

3 10

Hytrin

AAbbott

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Alzheimer's Disease

NCT06600880

Clinical

Trials by Indication[1]

MRI2 trials

Intra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRI

Completed·PPhoenix Children's Hospital··NCT03023566·250 enrolled

Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.

Completed· Bayer logo

Bayer·Phase 4·NCT00764387·166 enrolled

MPA2 trials

Crossover Comparison of MultiHance and Dotarem

Completed·BBracco Diagnostics, Inc·Phase 4·NCT02070380·179 enrolled

Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)

Terminated·GGuerbet·Phase 3·NCT00980681·13 enrolled

CAR2 trials

Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

Completed·GGuerbet·Phase 3·NCT01012674·211 enrolled

Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

Completed·GGuerbet·Phase 3·NCT01010932·222 enrolled

Brain Glioma1 trial

Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas

Completed·GGuerbet·Phase 3·NCT06057168·138 enrolled

Age1 trial

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

Completed·VVanderbilt University Medical Center··NCT03910114·500 enrolled

6 more indications

Interstitial Lung Disease1 trial

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

Recruiting·MMassachusetts General Hospital·Phase 2·NCT05417776·30 enrolled

Peripheral Arterial Disease1 trial

Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease

Completed·GGuerbet·Phase 4·NCT01026389·189 enrolled

Pediatric1 trial

DOTAREM Pharmacokinetics and Safety Study in Pediatric Subjects Aged < 2 Years

Completed·GGuerbet·Phase 4·NCT02411201·51 enrolled

Brain Tumors1 trial

Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors

Completed·GGuerbet·Phase 4·NCT02034708·279 enrolled

Central Nervous System1 trial

Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions

Completed·GGuerbet·Phase 3·NCT01211873·416 enrolled

Alzheimer's Disease1 trial

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

Not yet recruiting·—·Phase 1·NCT06600880·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Dotarem. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dotarem compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dotarem. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bayer

Dotarem

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

MRI2 trials

MPA2 trials

CAR2 trials

Brain Glioma1 trial

Age1 trial

Interstitial Lung Disease1 trial

Peripheral Arterial Disease1 trial

Pediatric1 trial

Brain Tumors1 trial

Central Nervous System1 trial

Alzheimer's Disease1 trial

References

Drug Info

Quick Facts

Related News